- 
                            
                            
                            
                                                            Key Brands
- 
                            
                            
                            
                                                            Statistics
- 
                            
                            
                            
                                                            Revenue
- 
                            
                            
                            
                                                            Contribution
- 
                            
                            
                            
                                                            Market data
| Brand | Therapeutic category | 
|---|---|
| Diprivan | General anaesthetic | 
| Durateston | Testosterone replacement therapy | 
| Lyrica | Anti-epileptic drugs | 
| Meticorten | Corticosteroid | 
| Magnesia Bisurada | Antacid | 
| Ovestin | Estrogen hormone replacement | 
				
				10
				
			
							Products
Launched
					Launched
(2023: 19)
				
				0
				
			
							Product
Recalls
					Recalls
(2023: 2)
				
				0
				%
			
							Average Staff
Turnover
					Turnover
(2023: 27%)
				
				0
				
			
							Work-related
Facilities
					Facilities
(2023: Nil)
				
				100
				
			
							Sales
Representatives
					Representatives
(2023: 228)
				
				610
				
			
							Permanent
Employees
					Employees
(June 2024)
				
				600
				
			
							Permanent
Employees
					Employees
(June 2023)
				
				5
				
			
							Products
Launched
					Launched
(2022: 20)
Product
Recalls
					Recalls
(2022: 1)
				
				5
				%
			
							Average Staff
Turnover
					Turnover
(2022: 22)
Work-related
Facilities
					Facilities
(2022: Nil)
				
				135
				
			
							Sales
Representatives
					Representatives
(2022: 235)
				
				250
				
			
							Permanent
Employees
					Employees
(June 2022: 714)
| Revenue | 2024 R’million | 2023 (CER) R’million | Change % | 
|---|---|---|---|
| Commercial Pharmaceuticals | 6 677 | 5 564 | 20 | 
| Prescription | 2 832 | 1 990 | 42 | 
| Injectables | 2 395 | 2 133 | 12 | 
| Over the counter | 1 450 | 1 441 | 1 | 
| Manufacturing | |||
| Finished dose form | 34 | 20 | 70 | 
| Total | 6 711 | 5 584 | 20 | 
Note: Commercial Pharmaceuticals’ revenue is by customer geography.
Contribution to Group revenue (%)
 
															- Rest of Group 85
- Americas 15
Revenue by segment (%)
 
															- Injectables36
- Prescription 25
- Over the counter 22
Contribution to Group revenue (%)
- Rest of Group 88
- Americas 12
Revenue by segment (%)
- Regional Brands 68
- Sterile Focus Brands 32
- Latin America is expected to grow 1,9% CAGR between 2024 and 2028
 
				





